ClinicalTrials.gg
Active, not recruitingNCT07228390Updated Nov 10, 2026

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

A Phase 2 interventional study of Ritlecitinib and Placebo in Hidradenitis Suppurativa, sponsored by Pfizer. Active, not recruiting at 57 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Updated Nov 10, 20261 site added11 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Enrollment
53rd of 139
128 · median 45
Started
2025
with 24 others
Phase 2
61 of 161
11 open now
Primary completion
2026-12
later than 14 of 54 live
Registered
143rd of 161
by date

Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 53rd largest by enrollment of the 139 interventional ones that give a count, is one of 25 that started in 2025, is one of 61 in phase 2, reaches primary completion later than 14 of the 54 other live ones, and was the 143rd registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidradenitis suppurativa (HS). HS is a disease causing long lasting painful red skin lumps.

This study is seeking participants who:

  • have moderate or severe HS
  • have previously received antibiotics for HS that did not help, or could not tolerate antibiotics Participants will be randomly (like a flip of coin) assigned to receive either the study medicine or a placebo (a pill that looks like the study medicine but does not contain any medicine). The study medicine or placebo will be taken by mouth once daily at home. For the first part of the study, participants will receive a loading (starting) dose. For the next part of the study, participants will receive a maintenance (ongoing) dose.

Participants will take part in the study for about 24 weeks (about 6 months). There will be about 10 study clinic visits: a screening visit, Day 1, and then every 1, 2, or 4 weeks until week 16. At each visit, participants will report on their health and have tests such as physical exams, blood and urine tests, vital signs, chest X-rays, ECGs, hearing tests, and questionnaires. Participants will record when they take the study medicine and their HS symptoms every day in an eDiary on a mobile phone.

The experiences of participants receiving the study medicine will be compared to those receiving placebo to help see if the study medicine is safe and effective.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Ritlecitinib
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Key Eligibility Criteria:

Inclusion criteria

Inclusion Criteria:

  1. Male or female participants ≥18 to ≤75 years of age.
  2. Participants with a diagnosis (based on clinical history and physical examination) of moderate to severe HS for at least 6 months prior to Screening Visit and inadequate response to at least 4-week (28 days) treatment with oral antibiotics for the treatment of HS.

Exclusion criteria

Exclusion Criteria:

  1. Presence of ≥20 draining fistulae at Screening or BL visit
  2. Evidence of other active skin disease or condition at screening
  3. Have a known immunodeficiency disorder
  4. Having a history of systemic infection requiring hospitalization or parenteral therapy, including history of infection with Mycobacterium TB
  5. Specific Viral Infection History (incl. history of herpes zoster, or Infection
  6. Current or recent history of severe, progressive, or uncontrolled other medical conditions
  7. Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Study Intervention

    Participants will receive one oral dose once daily (QD), starting with a loading dose of ritlecitinib for 8 weeks, followed by maintenance for 8 weeks.

    Drug: Ritlecitinib

  • Placebo comparator
    Placebo

    Participants will receive matching placebo.

    Drug: Placebo

Interventions

  • Participants will receive one oral dose once daily (QD), starting with a loading dose of ritlecitinib for 8 weeks, followed by maintenance for 8 weeks.

    Also known as: Investigational Product

  • DrugPlacebo

    Participant will receive matching placebo

06

What researchers measure

Primary outcomes

  1. Difference in proportion of responders based on Hidradenitis Suppurativa Clinical Response achieving at least 50% reduction from baseline (Hidradenitis Suppurativa Clinical Response HiSCR50) in patients with HS treated with ritlecitinib versus placebo.

    The difference in proportion of responders based on HiSCR50 response at Week 16 in patients with HS treated with ritlecitinib versus placebo.

    Time frame: Week 16

Secondary outcomes

  1. Proportion of participants achieving HiSCR50 response

    The difference in proportion of responders based on HiSCR50 response at Weeks 1, 2, 4, 6, 8 and 12 in patients with HS treated with ritlecitinib versus placebo

    Time frame: at Weeks 1, 2, 4, 6, 8 and Week 12.

  2. Proportion of participants achieving HiSCR75 response

    The difference in proportion of responders based on HISCR75 response at Weeks 1, 2, 4, 6, 8, 12 and 16 in patients with HS treated with ritlecitinib versus placebo

    Time frame: at Weeks 1, 2, 4, 6, 8, 12 and Week 16.

  3. Proportion of participants achieving HiSCR90 response

    The difference in proportion of responders based on HiSCR90 response at Weeks 1, 2, 4, 6, 8, 12 and 16 in patients with HS treated with ritlecitinib versus placebo

    Time frame: at Weeks 1, 2, 4, 6, 8, 12 and Week 16

  4. Response based on a on total abscess and inflammatory nodule count (AN Count) of 0 or 1

    The difference in proportion of responders based on a total AN count of 0 or 1 at Week 16 in patients with HS treated with ritlecitinib and placebo

    Time frame: Week 16

  5. Response based on a total AN count of 0, 1, or 2

    The difference in proportion of responders based on a total AN count of 0, 1 or 2 at Week 16 in patients with HS treated with ritlecitinib and placebo.

    Time frame: At week 16

  6. Percent change from Baseline(CFB) in total AN count

    The difference in mean percent CFB in total AN count at Weeks 1, 2, 4, 6, 8, 12 and 16 in patients with HS treated with ritlecitinib and placebo

    Time frame: Weeks 1, 2, 4, 6, 8, 12 and 16.

  7. Absolute score in Hidradenitis Suppurativa Investigator Global Assessment (HS-IGA)

    The difference in mean absolute score in HS-IGA at Weeks 1, 2, 4, 6, 8, 12 and 16 in patients with HS treated with ritlecitinib and placebo

    Time frame: at Weeks 1, 2, 4, 6, 8, 12 and 16

  8. CFB in Hidradenitis Suppurativa Investigator Global Assessment (HS-IGA)

    Mean CFB in HS-IGA at Weeks 1, 2, 4, 6, 8, 12 and 16 in patients with HS treated with ritlecitinib and placebo

    Time frame: at Weeks 1, 2, 4, 6, 8, 12 and 16

  9. Proportion of participants achieving a HS-IGA=0 or 1

    The difference in proportion of responders based on HS-IGA=0 or 1 at Weeks 1, 2, 4, 6, 8, 12 and 16 in patients with HS treated with ritlecitinib and placebo

    Time frame: Weeks 1, 2, 4, 6, 8, 12 and 16

  10. Participants who experience an HS flare, defined as at least a 25% increase in total AN count with a minimum increase of 2 relative to Baseline

    The difference in proportion of HS flare at Weeks 4, 8, 12 and 16 in patients with HS treated with ritlecitinib and placebo

    Time frame: Weeks 4, 8, 12 and 16.

  11. CFB in Hidradenitis Suppurativa Symptom Daily Diary (HSSDD)

    Time frame: Weeks 1, 2, 4, 6, 8, 12 and 16

  12. Skin pain NRS30 (numeric rating scale) response, at worst and on average, respectively among participants with baseline skin pain NRS ≥3

    Time frame: Weeks 1, 2, 4, 6, 8, 12, and 16

  13. Percent CFB in skin pain NRS, at worst and on average, respectively, in participants with baseline skin pain NRS ≥3

    Time frame: Weeks 1, 2, 4, 6, 8, 12, and 16

  14. CFB in skin pain NRS, at worst and on average, respectively

    Time frame: at Weeks 1, 2, 4, 6, 8, 12, and 16

  15. Skin pain NRS50 response, at worst and on average, respectively among participants with baseline skin pain NRS ≥3.

    Time frame: at Weeks 1, 2, 4, 6, 8, 12, and 16

  16. Skin pain NRS70 response, at worst and on average, respectively among participants with baseline skin pain NRS ≥3

    Time frame: at Weeks 1, 2, 4, 6, 8, 12, and 16,

  17. Incidence of treatment emergent adverse events (TEAE), adverse events (AE) and serious adverse events (SAE) leading to discontinuation

    Time frame: up to 24 Weeks

  18. Incidence of clinically significant laboratory abnormalities over time

    Time frame: up to 24 Weeks

  19. Absolute score and CFB in Hidradenitis Suppurativa Quality of Life (HiSQOL)

    Time frame: at Weeks 1, 2, 4, 6, 8, 12 and 16.

  20. Absolute score and % CFB in International Hidradenitis Suppurativa Severity Score System (IHS4)

    Time frame: Weeks 1, 2, 4, 6, 8, 12 and 16.

07

Study locations

57 sites
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 12 months is below that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2025
First posted
Nov 14, 2025
StartActual
Nov 13, 2025
Primary completionEst.
Dec 8, 2026
CompletionEst.
Jan 5, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 11 sites removed
Show site
  • USF - Carol and Frank Morsani Center for Advanced Healthcare-Clinical Research Center · Tampa, United States
Show 11 removed
  • Medical Dermatology Specialists · Phoenix, United States
  • Mayo Clinic Hospital · Phoenix, United States
  • Mayo Clinic Specialty Building · Phoenix, United States
  • Mayo Clinic · Scottsdale, United States
  • USF Health · Tampa, United States
  • Skin Specialists, PC dba Schlessinger MD · Omaha, United States
  • Papageorgiou General Hospital of Thessaloniki · Thessaloniki, Greece
  • Państwowy Instytut Medyczny MSWiA · Warsaw, Poland
  • University General Hospital of Larissa · Larissa, Greece
  • Uniwersytecki Szpital kliniczny im. F. Chopina w Rzeszowie · Rzeszów, Poland
  • Trialmed CRS - Warszawa · Warsaw, Poland
across 2 updates, Oct 20, 2026 – Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    3 sites removed
    Show 3 removed
    • University General Hospital of Larissa · Larissa, Greece
    • Uniwersytecki Szpital kliniczny im. F. Chopina w Rzeszowie · Rzeszów, Poland
    • Trialmed CRS - Warszawa · Warsaw, Poland
    + 1 other change: verification date
  2. Oct 20, 2026
    1 site added, 8 sites removed
    Show site
    • USF - Carol and Frank Morsani Center for Advanced Healthcare-Clinical Research Center · Tampa, United States
    Show 8 removed
    • Medical Dermatology Specialists · Phoenix, United States
    • Mayo Clinic Hospital · Phoenix, United States
    • Mayo Clinic Specialty Building · Phoenix, United States
    • Mayo Clinic · Scottsdale, United States
    • USF Health · Tampa, United States
    • Skin Specialists, PC dba Schlessinger MD · Omaha, United States
    • Papageorgiou General Hospital of Thessaloniki · Thessaloniki, Greece
    • Państwowy Instytut Medyczny MSWiA · Warsaw, Poland
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07228390
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 14, 2025
Start date
Nov 13, 2025
Primary completion
Dec 8, 2026 (estimated)
Completion
Jan 5, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion